JP2019522050A5 - - Google Patents

Download PDF

Info

Publication number
JP2019522050A5
JP2019522050A5 JP2019518185A JP2019518185A JP2019522050A5 JP 2019522050 A5 JP2019522050 A5 JP 2019522050A5 JP 2019518185 A JP2019518185 A JP 2019518185A JP 2019518185 A JP2019518185 A JP 2019518185A JP 2019522050 A5 JP2019522050 A5 JP 2019522050A5
Authority
JP
Japan
Prior art keywords
optionally substituted
antibody
antigen
binding fragment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019518185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/038151 external-priority patent/WO2017219025A1/en
Publication of JP2019522050A publication Critical patent/JP2019522050A/ja
Publication of JP2019522050A5 publication Critical patent/JP2019522050A5/ja
Priority to JP2022116511A priority Critical patent/JP2022163075A/ja
Priority to JP2023208327A priority patent/JP2024037832A/ja
Pending legal-status Critical Current

Links

JP2019518185A 2016-06-17 2017-06-19 細胞の枯渇のための組成物および方法 Pending JP2019522050A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022116511A JP2022163075A (ja) 2016-06-17 2022-07-21 細胞の枯渇のための組成物および方法
JP2023208327A JP2024037832A (ja) 2016-06-17 2023-12-11 細胞の枯渇のための組成物および方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662351725P 2016-06-17 2016-06-17
US201662351778P 2016-06-17 2016-06-17
US62/351,725 2016-06-17
US62/351,778 2016-06-17
US201662437729P 2016-12-22 2016-12-22
US201662437756P 2016-12-22 2016-12-22
US62/437,756 2016-12-22
US62/437,729 2016-12-22
US201762448782P 2017-01-20 2017-01-20
US201762448768P 2017-01-20 2017-01-20
US62/448,782 2017-01-20
US62/448,768 2017-01-20
PCT/US2017/038151 WO2017219025A1 (en) 2016-06-17 2017-06-19 Compositions and methods for the depletion of cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022116511A Division JP2022163075A (ja) 2016-06-17 2022-07-21 細胞の枯渇のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2019522050A JP2019522050A (ja) 2019-08-08
JP2019522050A5 true JP2019522050A5 (cg-RX-API-DMAC7.html) 2020-07-30

Family

ID=60664586

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019518185A Pending JP2019522050A (ja) 2016-06-17 2017-06-19 細胞の枯渇のための組成物および方法
JP2022116511A Pending JP2022163075A (ja) 2016-06-17 2022-07-21 細胞の枯渇のための組成物および方法
JP2023208327A Pending JP2024037832A (ja) 2016-06-17 2023-12-11 細胞の枯渇のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022116511A Pending JP2022163075A (ja) 2016-06-17 2022-07-21 細胞の枯渇のための組成物および方法
JP2023208327A Pending JP2024037832A (ja) 2016-06-17 2023-12-11 細胞の枯渇のための組成物および方法

Country Status (13)

Country Link
US (5) US20190328901A1 (cg-RX-API-DMAC7.html)
EP (1) EP3471772A4 (cg-RX-API-DMAC7.html)
JP (3) JP2019522050A (cg-RX-API-DMAC7.html)
KR (2) KR20190039085A (cg-RX-API-DMAC7.html)
CN (1) CN109641051A (cg-RX-API-DMAC7.html)
AU (3) AU2017204139B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018076263A2 (cg-RX-API-DMAC7.html)
CA (1) CA3028145A1 (cg-RX-API-DMAC7.html)
IL (1) IL263743A (cg-RX-API-DMAC7.html)
MA (1) MA45407A (cg-RX-API-DMAC7.html)
MX (1) MX2018015683A (cg-RX-API-DMAC7.html)
SG (1) SG11201811292RA (cg-RX-API-DMAC7.html)
WO (1) WO2017219025A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3439699A4 (en) 2016-04-04 2019-11-20 Hemogenyx LLC METHOD FOR ELIMINATING HEMATOPOETIC STEM CELLS / HEMATOPOIDIC PRECURSOR CELLS (HSC / HP) IN A PATIENT WITH BI-SPECIFIC ANTIBODIES
AU2018302098A1 (en) 2017-07-18 2020-02-20 Csl Behring Gene Therapy, Inc. Compositions and methods for treating beta-hemoglobinopathies
CN111670052A (zh) 2017-11-29 2020-09-15 美真达治疗公司 用于耗尽cd5+细胞的组合物和方法
KR20250134703A (ko) 2018-05-11 2025-09-11 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법
CA3098103A1 (en) * 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
AU2019311077B2 (en) * 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
AU2019310430A1 (en) * 2018-07-23 2021-02-25 Magenta Therapeutics, Inc. Use of an anti-CD2 antibody drug conjugate (ADC) in allogeneic cell therapy
WO2020092654A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Anti-cd45 antibodies and conjugates thereof
KR20210086683A (ko) * 2018-10-30 2021-07-08 마젠타 테라퓨틱스 인코포레이티드 동종이형 조혈 줄기 세포 이식 방법
CN113518825A (zh) 2018-12-23 2021-10-19 美国杰特贝林生物制品有限公司 Wiskott-aldrich综合征的造血干细胞基因疗法
JP2022518150A (ja) * 2019-01-07 2022-03-14 マジェンタ セラピューティクス インコーポレイテッド 細胞療法での抗cd45抗体-薬物結合体(adc)の使用経験
EP3958910A4 (en) * 2019-04-24 2023-08-02 Magenta Therapeutics, Inc. ANTI-CD45-DRUG ANTIBODY CONJUGATES AND THEIR USES
JP2022531141A (ja) * 2019-04-24 2022-07-06 マジェンタ セラピューティクス インコーポレイテッド 遺伝子治療のコンディショニング方法
CA3137568A1 (en) * 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
EP3980066A4 (en) * 2019-06-04 2023-08-02 Magenta Therapeutics, Inc. Methods and compositions for treating autoimmune diseases
KR102776925B1 (ko) * 2019-06-25 2025-03-11 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
WO2021007266A1 (en) * 2019-07-09 2021-01-14 Hemogenyx Llc Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
WO2021016668A1 (en) * 2019-07-30 2021-02-04 Dendrocyte Biotech Pty Ltd Immunoconjugate
JP7716399B2 (ja) * 2019-11-01 2025-07-31 ブイオーアール バイオファーマ インコーポレーテッド 抗-cd45抗体及びそのコンジュゲート
AU2021224663A1 (en) * 2020-02-18 2022-09-08 Vor Biopharma, Inc. Compositions and methods for allogeneic transplantation
US20230158104A1 (en) * 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in autoimmune conditions
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
WO2023118608A1 (en) 2021-12-23 2023-06-29 Universität Basel Discernible cell surface protein variants of cd45 for use in cell therapy

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
WO1990009799A1 (en) 1989-02-23 1990-09-07 Colorado State University Research Foundation GnRH ANALOGS FOR DESTROYING GONADOTROPHS
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6024957A (en) 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US7265212B2 (en) 2001-12-03 2007-09-04 Amgen Fremont Inc. Anti-CD45RB antibodies
RU2386639C2 (ru) * 2003-09-18 2010-04-20 Новартис Аг Связывающие молекулы, обладающие терапевтической активностью
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1661584A1 (en) 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
WO2007092196A2 (en) 2006-01-27 2007-08-16 Cellerant Therapeutics, Inc. Compositions and methods for treating myeloid proliferative disorders
JP2009529522A (ja) 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
EP1859811B1 (en) 2006-05-27 2011-08-24 Faulstich, Heinz, Dr. Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
AU2007307652A1 (en) * 2006-10-10 2008-04-17 Squicor Compositions and methods for treating and diagnosing cancers
SI3255061T1 (sl) * 2006-11-03 2021-09-30 The Board Of Trustees Of The Leland Stanford Junior University Selektivno imunsko osiromašenje niše endogenih matičnih celic za vsaditev
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
PE20120877A1 (es) * 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
ES2784829T3 (es) 2009-04-08 2020-10-01 Faulstich Heinz Dr Componentes de unión a la superficie de células terapéuticas provistos de amatoxina diseñados para terapia de tumores
MX2011010469A (es) 2009-04-08 2012-03-14 Deutsches Krebsforsch Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
BR112012026801B8 (pt) 2010-04-15 2021-05-25 Medimmune Ltd conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
EP2436398B1 (en) 2010-09-30 2013-01-23 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkers
EP2497499A1 (en) * 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
MX359513B (es) * 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
BR122020001787A8 (pt) 2011-05-08 2023-04-25 Legochem Biosciences Inc Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
MX375987B (es) 2011-10-14 2025-03-07 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
CA2850264C (en) 2011-10-14 2019-11-05 Spirogen Sarl Pyrrolobenzodiazepines
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
WO2014043403A1 (en) 2012-09-12 2014-03-20 Agensys, Inc. Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
US9324898B2 (en) * 2012-09-25 2016-04-26 Alliance For Sustainable Energy, Llc Varying cadmium telluride growth temperature during deposition to increase solar cell reliability
CA2888445A1 (en) 2012-11-30 2014-06-05 Novartis Ag Methods for making conjugates from disulfide-containing proteins
US11116819B2 (en) 2013-02-28 2021-09-14 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
AU2014299561B2 (en) 2013-06-24 2017-06-08 Ablbio Antibody-drug conjugate having improved stability and use thereof
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
JP6321687B2 (ja) * 2014-03-10 2018-05-09 ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング アマトキシン誘導体
HK1231367A1 (zh) 2014-06-02 2017-12-22 Regeneron Pharmaceuticals, Inc. 抗体药物偶联物、试剂和制备方法及其治疗用途
EP3174902B1 (en) * 2014-08-01 2019-04-17 Institut National de la Sante et de la Recherche Medicale (INSERM) An anti-cd45rc antibody for use as drug
RU2715905C2 (ru) 2014-10-01 2020-03-04 МЕДИММЬЮН, ЭлЭлСи Способ конъюгации полипептида
EP3209334A2 (en) 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use
WO2016071856A1 (en) * 2014-11-06 2016-05-12 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
EP3026060A1 (en) * 2014-11-26 2016-06-01 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for CD45R0
US9729129B2 (en) * 2014-12-05 2017-08-08 Bhaskar Gopalan System and method for reducing metastability in CMOS flip-flops
US20160220687A1 (en) 2015-02-02 2016-08-04 National Guard Health Affairs Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer
CN114395050B (zh) 2015-03-09 2025-03-14 海德堡医药有限责任公司 鹅膏毒素-抗体轭合物
EP4249916A3 (en) 2015-04-06 2023-11-01 President and Fellows of Harvard College Compositions and methods for non-myeloablative conditioning
EP3297684B1 (en) 2015-05-21 2020-12-23 Actinium Pharmaceuticals, Inc. Infusion administration of conjugated monoclonal antibodies
WO2017051249A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MX378847B (es) 2015-11-27 2025-03-11 Heidelberg Pharma Res Gmbh Nuevos derivados de gamma-amanitina
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
CA3016901C (en) 2016-03-07 2023-06-13 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
NZ744936A (en) 2016-04-20 2022-01-28 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
WO2017191579A1 (en) 2016-05-05 2017-11-09 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
CA3022802A1 (en) 2016-05-27 2017-11-30 Actinium Pharmaceuticals, Inc. Low dose antibody-based methods for treating hematologic malignancies
CA3025931A1 (en) 2016-05-31 2017-12-07 Sorrento Therapeutics, Inc. Antibody drug conjugates having derivatives of amatoxin as the drug
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
SG11201903644VA (en) 2016-08-29 2019-05-30 Pdi Pharm Development Int Ag Provision of a therapeutically active cell product
US10112266B2 (en) * 2016-09-09 2018-10-30 Baltic Innovation Holding PRO, AS Pressed thermite rod for a self-contained portable cutting device
EP3526260A4 (en) * 2016-10-13 2020-11-18 President and Fellows of Harvard College NON-MYELOABLATIVE PACKAGING COMPOSITIONS AND METHODS
KR102455175B1 (ko) 2016-12-23 2022-10-17 하이델베르크 파마 리서치 게엠베하 아마니틴 접합체
SG10202102897PA (en) 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
US20180214524A1 (en) 2017-01-30 2018-08-02 The Board Of Trustees Of The Leland Stanford Junior University Non-genotoxic conditioning regimen for stem cell transplantation
US11420971B2 (en) 2017-08-07 2022-08-23 Heidelberg Pharma Research Gmbh Method for synthesizing amanitins

Similar Documents

Publication Publication Date Title
JP2019522050A5 (cg-RX-API-DMAC7.html)
WO2019108863A4 (en) Compositions and methods for the depletion of cd5+ cells
JP2021500391A5 (cg-RX-API-DMAC7.html)
WO2019084064A4 (en) Compositions and methods for the depletion of cd117+ cells
JP2019522680A5 (cg-RX-API-DMAC7.html)
CN110461876B (zh) 用于耗尽cd137+细胞的组合物和方法
WO2019108860A4 (en) Compositions and methods for the depletion of cd2+ cells
KR102144317B1 (ko) 항-lag-3 항체 및 그것의 사용
ES2649155T3 (es) Anticuerpos anti-OX40 y procedimientos de uso de los mismos
JP2020513791A5 (cg-RX-API-DMAC7.html)
ES2732081T3 (es) Anticuerpos anti-FcRn
JP6998857B2 (ja) Cd79に結合する抗体分子
JP2021504414A5 (cg-RX-API-DMAC7.html)
JP2021519295A (ja) 抗cd38抗体の皮下投薬
KR20180119653A (ko) Tigit에 대한 항체
RU2008149918A (ru) Антитела к nkg2a и их применения
RU2012142311A (ru) Интерлейкин-13-связывающие белки
RU2015118180A (ru) Антитела к бета-амилоиду
WO2013072523A4 (en) Bi-specific antibodies for medical use
TW201902925A (zh) 抗cd40抗體、其抗原結合片段及其醫藥用途
CN110343180B (zh) 抗ctla-4抗体及其应用
KR20220030934A (ko) 항-gal9 면역-억제 결합 분자
EP3959242A1 (en) Anthracycline antibody-drug conjugates and uses thereof
AU2021391779A1 (en) Modulating the immune response using anti-cd30 antibody-drug conjugates
CN114206358A (zh) T细胞消耗疗法